| |
Monday, June 9, 2025 | 11am ET / 8am PT Get an insider’s look at the Bio International Convention in Boston before it even begins! Whether you’re attending in person or following along remotely, this exclusive virtual event will ensure you’re up to speed on the latest industry insights, emerging trends, and key players everyone is talking about. Don't miss out, register now. 
|
|
Today’s Big NewsMay 29, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now. 
|
|
| By Gabrielle Masson After communicating with the FDA about font sizes for potential packaging on its investigational injection, Stealth Biotherapeutics’ CEO thought approval for the ultrarare genetic disease treatment was imminent. |
|
|
|
By Fraiser Kansteiner Some two weeks after the public comment period closed for the Trump administration’s Section 232 investigation into the national security implications of pharmaceutical imports, a wide range of drugmakers, trade groups and foreign governments have largely aligned in opposition to potential industry-specific tariffs. |
By Eric Sagonowsky After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in consecutive years. |
By Kevin Dunleavy Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease treatment Tryptyr. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now. 
|
|
By Nick Paul Taylor COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. Fourteen months after an old tweet caused Pfizer new problems, pandemic-era social media posts linked to the drugmaker have again been found to have brought discredit to the pharma industry. |
By Nick Paul Taylor The Department of Health and Human Services has axed a $590 million contract with Moderna, raising doubts about how the biotech will fund late-phase development of a pandemic bird flu vaccine. |
By Conor Hale Salvia BioElectronics’ neuromodulation device, with paper-thin implants placed under the skin at the front and back of the head, is being tested in a blinded study. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Gabrielle Masson Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team. |
By Andrea Park Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Tuesday, June 17, 2025 | 11am ET / 8am PT Join experts from NIBRT and Securecell AG to explore how advanced Process Analytical Technologies (PAT) are transforming bioprocessing. Register now. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
